Fibroblast Growth Factor Family in the Progression of Prostate Cancer.
fibroblast growth factor
fibroblast growth factor receptor
prostate cancer
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
04 Feb 2019
04 Feb 2019
Historique:
received:
10
01
2019
revised:
23
01
2019
accepted:
31
01
2019
entrez:
6
2
2019
pubmed:
6
2
2019
medline:
6
2
2019
Statut:
epublish
Résumé
Fibroblast growth factors (FGFs) and FGF receptors (FGFRs) play an important role in the maintenance of tissue homeostasis and the development and differentiation of prostate tissue through epithelial-stromal interactions. Aberrations of this signaling are linked to the development and progression of prostate cancer (PCa). The FGF family includes two subfamilies, paracrine FGFs and endocrine FGFs. Paracrine FGFs directly bind the extracellular domain of FGFRs and act as a growth factor through the activation of tyrosine kinase signaling. Endocrine FGFs have a low affinity of heparin/heparan sulfate and are easy to circulate in serum. Their biological function is exerted as both a growth factor binding FGFRs with co-receptors and as an endocrine molecule. Many studies have demonstrated the significance of these FGFs and FGFRs in the development and progression of PCa. Herein, we discuss the current knowledge regarding the role of FGFs and FGFRs-including paracrine FGFs, endocrine FGFs, and FGFRs-in the development and progression of PCa, focusing on the representative molecules in each subfamily.
Identifiants
pubmed: 30720727
pii: jcm8020183
doi: 10.3390/jcm8020183
pmc: PMC6406580
pii:
doi:
Types de publication
Journal Article
Review
Langues
eng
Références
J Biol Chem. 1999 Apr 30;274(18):12827-34
pubmed: 10212269
Cytokine. 1999 Oct;11(10):729-35
pubmed: 10525310
Glia. 2000 May;30(3):231-41
pubmed: 10756073
J Neurosci Res. 2000 Aug 1;61(3):273-87
pubmed: 10900074
Breast Cancer. 1999 Oct 25;6(4):320-324
pubmed: 11091737
Am J Pathol. 2002 Jun;160(6):2295-307
pubmed: 12057932
Cancer Res. 2004 Jul 1;64(13):4555-62
pubmed: 15231666
Prostate. 2004 Nov 1;61(3):236-42
pubmed: 15368475
Bone. 2005 Jun;36(6):971-7
pubmed: 15869926
Am J Physiol Gastrointest Liver Physiol. 2005 Dec;289(6):G1036-42
pubmed: 16020653
Cancer Res. 2006 Feb 1;66(3):1354-62
pubmed: 16452189
Cancer Res. 2006 Feb 15;66(4):2188-94
pubmed: 16489020
J Biol Chem. 2006 Jun 9;281(23):15694-700
pubmed: 16597617
Development. 2007 Feb;134(4):723-34
pubmed: 17215304
Proc Natl Acad Sci U S A. 2007 May 1;104(18):7432-7
pubmed: 17452648
Oncogene. 2008 Jan 3;27(1):85-97
pubmed: 17599042
J Biol Chem. 2007 Sep 14;282(37):26687-95
pubmed: 17623664
J Biol Chem. 2007 Sep 14;282(37):27277-84
pubmed: 17627937
Cancer Cell. 2007 Dec;12(6):559-71
pubmed: 18068632
Cancer Cell. 2007 Dec;12(6):572-85
pubmed: 18068633
Development. 2008 Feb;135(4):775-84
pubmed: 18184727
Endocr Rev. 2008 Apr;29(2):193-216
pubmed: 18216218
Cancer Res. 2008 Jul 1;68(13):5086-95
pubmed: 18593907
J Clin Invest. 2008 Aug;118(8):2697-710
pubmed: 18618013
Anticancer Res. 2008 Jul-Aug;28(4B):2141-6
pubmed: 18751387
Nat Genet. 2009 Mar;41(3):289-98
pubmed: 19219044
Nat Rev Drug Discov. 2009 Mar;8(3):235-53
pubmed: 19247306
J Neurosci Res. 2009 Aug 1;87(10):2201-10
pubmed: 19267409
Int J Cancer. 2009 Aug 15;125(4):807-15
pubmed: 19358281
Mol Cell Biol. 2009 Sep;29(17):4663-78
pubmed: 19564416
Nat Rev Cancer. 2010 Feb;10(2):116-29
pubmed: 20094046
Biosci Rep. 2010 Apr 09;30(5):285-91
pubmed: 20406196
J Biochem. 2011 Feb;149(2):121-30
pubmed: 20940169
Prostate. 2011 Nov;71(15):1691-700
pubmed: 21446013
Biochem J. 2011 Jul 15;437(2):199-213
pubmed: 21711248
Prostate Cancer Prostatic Dis. 2012 Mar;15(1):8-14
pubmed: 22006051
Cell Metab. 2012 Sep 5;16(3):387-93
pubmed: 22958921
Cancer Res. 2013 Feb 15;73(4):1400-10
pubmed: 23243019
Cancer Res. 2013 Apr 15;73(8):2551-62
pubmed: 23440425
Clin Cancer Res. 2013 Nov 1;19(21):5856-66
pubmed: 24052019
Anticancer Res. 2014 Feb;34(2):695-700
pubmed: 24511001
Oncol Rep. 2014 Jul;32(1):65-70
pubmed: 24839986
Prostate. 2015 Jul 1;75(10):1092-101
pubmed: 25854696
Oncotarget. 2015 Jul 10;6(19):17291-301
pubmed: 26019137
J Biol Chem. 2015 Jul 17;290(29):17753-61
pubmed: 26032417
Oncogene. 2016 Apr 7;35(14):1750-9
pubmed: 26096936
Int J Biol Sci. 2015 Jun 11;11(8):948-60
pubmed: 26157349
Cancer Cell. 2015 Aug 10;28(2):225-39
pubmed: 26267536
Nat Rev Drug Discov. 2016 Jan;15(1):51-69
pubmed: 26567701
Dig Dis. 2017;35(3):158-165
pubmed: 28249259
Cancer Cell. 2017 Oct 9;32(4):474-489.e6
pubmed: 29017058
Oncotarget. 2017 Aug 1;8(47):82583-82592
pubmed: 29137286
Cancer Lett. 2018 Apr 1;418:109-118
pubmed: 29337106
Neoplasia. 2018 Mar;20(3):233-243
pubmed: 29444487
Oncotarget. 2018 Feb 12;9(18):14456-14471
pubmed: 29581856
Oncol Rep. 2018 Jul;40(1):217-225
pubmed: 29749458
Urol Oncol. 2018 Aug;36(8):365.e15-365.e26
pubmed: 29887238
Cancer Res. 2018 Aug 15;78(16):4459-4470
pubmed: 29891507
J Biol Chem. 2018 Sep 21;293(38):14839-14849
pubmed: 30093411
Cancer Res. 1997 Dec 1;57(23):5369-78
pubmed: 9393762
Oncogene. 1997 Dec 18;15(25):3059-65
pubmed: 9444954
Cancer Res. 1998 Apr 1;58(7):1509-14
pubmed: 9537256
Oncol Rep. 1999 Jan-Feb;6(1):87-92
pubmed: 9864407